1. Fenske DB, Chonn A, Cullis PR. Liposomal nanomedicines: an emerging field. Toxicol Pathol. 2008;36(1):21–9.
2. Sapra P, Allen TM. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res. 2003;42(5):439–62.
3. Elmroth K, Stenerlow B. DNA-incorporated 125I induces more than one double-strand break per decay in mammalian cells. Radiat Res. 2005;163(4):369–73.
4. Lundqvist H, Stenerlöw B, Gedda L. The Auger effect in molecular-targeting therapy. In: Stigbrand T, Adams G, Carlsson J, editors. Targeted radionuclide tumor therapy. Springer Sciences: Business Media B.V; 2008. p. 197–216.
5. Chen P, Wang J, Hope K, Jin L, Dick J, Cameron R, Brandwein J, Minden M, Reilly RM. Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells. J Nucl Med. 2006;47(5):827–36.